Leflunomide in Systemic Lupus Erythematosus

A Randomized, Double-Blind, Placebo Controlled Clinical Trial of Leflunomide in Systemic Lupus Erythematosus (SLE)

A pilot study to evaluate the efficacy and safety of leflunomide in SLE patients with active disease who are refractory to cyclophosphamide

Inclusion Criteria:

• Fulfill the revised ACR criteria for SLE with either evidence of active disease according to SLE Disease Activity Index (SLEDAI)

Exclusion Criteria:

• Patients who are pregnant or nursing women, or those with life threatening disease
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.